The NDA submission follows the successful completion of a pivotal Phase III global clinical trial
Takeda will seek an external partner to leverage its cell therapy platform technologies
Proposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio
The acquisition positions ACL Digital as an end-to-end provider of global clinical research and data CRO solutions
India currently hosts more than 10,075 biotech startups
Hyperion results presented at ERS 2025 and simultaneously published in the New England Journal of Medicine
This milestone marks the first-ever NDA submission to the U.S. FDA for a drug, fully discovered and developed by an Indian pharmaceutical company
Eliquis (apixaban) available at more than 40 per cent discount; Sotyktu to be offered at more than 80 per cent discount to current list price
The platform is being introduced to expand access to treatments for people living with chronic conditions
Subscribe To Our Newsletter & Stay Updated